Echosens

🍟 Did you know that consuming fast food for 20% or more of your daily calories can lead to higher levels of fat in your liver? If only liver screening could be as easily accessible as hitting the drive-thru. With a growing number of clinics and hospitals introducing liver health management programs that include non-invasive tests like FibroScan®, it’s possible! Informed choices reduce risk—and early screening saves lives. #GetScreened #LiverHealthMatters

Chaque année en France, environ 8200 cas de cancer du foie sont diagnostiqués, avec une prédominance chez les hommes. Selon les chercheurs du Centre international de recherche sur le cancer (CIRC), cette maladie est en constante progression et pourrait augmenter de plus de 55 % d’ici 2040. Les facteurs responsables incluent la hausse de l’obésité, du diabète de type 2 et la persistance de causes classiques telles que l’alcoolisme et les hépatites B ou C. 🔍 Un diagnostic souvent tardif : Le cancer du foie reste longtemps silencieux, ce qui entraîne souvent un diagnostic à un stade avancé. Il est donc crucial de sensibiliser et de mettre en œuvre des stratégies de dépistage précoce pour améliorer les chances de traitement et de survie. Pour diagnostiquer une maladie du foie et en évaluer sa gravité, l’élastographie avec l’appareil #FibroScan® est utilisée afin de mesurer l’élasticité du foie. Le Pr Yves Menu explique que cette technique permet de renseigner rapidement sur la présence éventuelle d’une fibrose hépatique et d’une surcharge en graisse du foie. Or une fibrose pouvant évoluer en cirrhose puis en cancer avec le temps, les patients chez qui on la détecte feront l’objet d’un suivi régulier. Pour lire l’article en entier 👉 https://lnkd.in/eUBEgimw Pour en savoir plus sur notre solution non-invasive de prise en charge globale des maladies chroniques du foie 👉 https://lnkd.in/echXpTs3 #LiverHealthMatters #Diabète #Obésité

Dr. Naim Alkhouri, MD, FAASLD of Arizona Liver Health says he rarely uses biopsies to identify the severity of fatty liver disease. The test he uses the most? FibroScan®. #GetScreened #LiverHealthMatters

Recently, we hosted a private dinner reception in the Tampa, FL area, where two of our physician partners presented on various topics related to liver disease management. Both speakers, Dr. Guy Neff (FL) and Dr. Tejas Joshi (WV), were early adopters of our new Guided VCTE™ technology and spoke to a large group of gastroenterologists about the critical role #FibroScan® plays in optimizing liver assessment in both the clinical practice and research setting. Thank you to both speakers for sharing their invaluable expertise, knowledge, and perspective. Interested in learning more about our revolutionary Guided VCTE™ technology? Click here 👉 https://lnkd.in/eSNc6DUc #LiverHealthMatters

🎉 Exciting milestone achieved in the Liverscreen project: we are thrilled to announce that 30,000 patients have now been enrolled in the Liverscreen study! The Liverscreen project is dedicated to demonstrating the efficacy of using #FibroScan as a first-line tool in primary care to identify patients who need to be referred to a Hepatologist, ensuring early and accurate diagnosis of liver conditions.  As a major partner of this consortium, Echosens is committed to advancing liver health and improving patient outcomes. We extend our heartfelt thanks to all the participants, healthcare professionals, and other partners who have contributed to this significant achievement. #LiverHealthMatters

⏰ J-1 ! Assistez demain à notre #webinaire sur la prise en charge des maladies hépatiques en libéral à l’aide de #FibroScan® avec Dr. Dann Ouizeman. 👉 Découvrez ses dernières recommandations sur LSM by VCTE™ & CAP™ pour l’évaluation de la fibrose et de la stéatose ainsi que son retour d'expérience avec la solution dans sa pratique clinique au quotidien. Vous aurez aussi l’occasion de découvrir et échanger sur la gamme FibroScan® et notre dernière innovation, Guided VCTE™. 📍Inscrivez-vous ici : https://lnkd.in/e4vQYJpS #LiverHealthMatters

“Our goal is to increase the accessibility of liver assessments, and we believe that empowering healthcare providers with a technology that is accurate, simple, and fast is the key.” – Laurent Sandrin, founder and Chief Science & Innovation Officer of Echosens. Thanks to Applied Radiology for featuring the recent global launch of our next-generation #FibroScan® with Guided VCTE™ technology. 👉 https://lnkd.in/eX8kU4_X #LiverHealthMatters

We are proud to partner with VELA - Sail For Goods to be able to transport our medical devices by sea, thus reducing our carbon impact. This action is in line with our strong #ESG commitment, for which we were awarded the Gold Medal in recognition of our EcoVadis, rewarding our long-term engagement to corporate social responsibility. #LiverHealthMatters

#FibroScan® now has digital connectivity with our new Liver Health Management (LHM) platform. 🔄 Streamline the transfer of FibroScan® results to the LHM platform to help you make data-driven care decisions. 📝 Enhance FibroScan® exams with Scores and interpretation tools. 🩺 Access tools, resources, and clinical care pathways to help monitor and manage liver disease. Learn more 👉 https://lnkd.in/gZCuQWCs #LiverHealthMatters

✴️ Ready to streamline the way you manage and monitor liver health? Introducing the Liver Health Management (LHM) platform from Echosens. ➡️ Connect your #FibroScan® today! Learn more: https://lnkd.in/gZCuQWCs #LiverHealthMatters